Effects of neoadjuvant-adjuvant pertuzumab in HER2- positive early breast cancer
The final analysis of phase III PEONY trial confirms a positive benefit/risk ratio of neoadjuvant/adjuvant pertuzumab, trastuzumab, and docetaxel treatment in patients with HER2+ early breast cancer